Gleave M - Search Results

1

Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer.

Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M, Zoubeidi A. Shiota M, et al. Among authors: gleave m. Cancer Res. 2013 May 15;73(10):3109-19. doi: 10.1158/0008-5472.CAN-12-3979. Epub 2013 Mar 14. Cancer Res. 2013. PMID: 23492367

2

Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.

Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Rabbani F, et al. Among authors: gleave me. Cancer. 1996 Aug 1;78(3):480-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V. Cancer. 1996. PMID: 8697394

3

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

4

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

5

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

6

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

Miayake H, Tolcher A, Gleave ME. Miayake H, et al. Among authors: gleave me. J Natl Cancer Inst. 2000 Jan 5;92(1):34-41. doi: 10.1093/jnci/92.1.34. J Natl Cancer Inst. 2000. PMID: 10620631

7

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jan 1;60(1):170-6. Cancer Res. 2000. PMID: 10646870

8

Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.

Miyake H, Nelson C, Rennie PS, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 May 1;60(9):2547-54. Cancer Res. 2000. PMID: 10811138

9

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

Miyake H, Chi KN, Gleave ME. Miyake H, et al. Among authors: gleave me. Clin Cancer Res. 2000 May;6(5):1655-63. Clin Cancer Res. 2000. PMID: 10815883

10

Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.

Miyake H, Pollak M, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 2000 Jun 1;60(11):3058-64. Cancer Res. 2000. PMID: 10850457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

694 results

Search Page

Filters